top of page
The Professional Network for Healthcare Experts
Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.
nuaxia
Sep 42 min read
Cipla licenses HER2 bispecific ADC TQB2102 from Sino Biopharmaceutical
The agreement gives Cipla exclusive rights to develop and commercialise the investigational HER2-targeted bispecific antibody-drug conjugate TQB2102 across India, South Africa and five additional emerging markets.
nuaxia
Sep 22 min read
bottom of page